文献速递免疫规划卫生政策与健康促进

疫苗成本效果分析中的家庭溢出效应

Family spillover effects in cost-effectiveness analyses of vaccines.
PubMed 文献 · Vaccine · 2025-09-19

通过Tufts CEA注册库系统综述2013年1月至2022年12月发表的英文疫苗成本效果分析,评估家庭溢出效应的纳入频率及其对结果的影响。在268项纳入分析中,137项涉及四种主要疫苗,其中65项(47.4%)纳入家庭溢出效应,主要为时间成本;纳入后多数分析结果更 favorable。

要点

  • 约半数疫苗成本效果分析未纳入家庭溢出效应。
  • 纳入者多仅计入时间成本,极少纳入家庭健康效应。
  • 纳入家庭溢出效应后,多数ICER降低或转为成本节约。

核心结论

  • 样本中约半数疫苗成本效果分析未纳入家庭溢出效应;纳入者多仅增加家庭溢出成本而极少纳入家庭健康效应,结果总体更 favorable。作者认为未来疫苗成本效果分析应适当纳入家庭溢出效应以反映疫苗全部价值并支持循证决策。

研究设计与样本

  • 利用Tufts CEA注册库进行系统综述,检索2013年1月至2022年12月发表的、从社会视角开展的英文疫苗成本效果分析。

主要发现

  • 268项符合纳入标准的疫苗成本效果分析中,前四位疫苗为:人乳头瘤病毒(n=21)、流感(n=57)、肺炎球菌(n=37)、轮状病毒(n=25),共137项研究(占51%)。
  • 137项研究中65项(47.4%)纳入家庭溢出效应,其中64项(98.5%)为时间成本,仅4项(6.2%)纳入家庭溢出健康效应。
  • 从30项研究生成266对增量成本效果比(ICER),每对分别计算纳入与不纳入家庭溢出效应的ICER;29对(10.9%)因纳入家庭溢出效应从正ICER(正成本、正收益)转为成本节约(负成本、正收益)。
  • 30对(11.3%)在纳入与不纳入时均保持成本节约,207对(77.8%)均保持正ICER;其中206对(99.5%)平均ICER降低18.8%,1对(0.5%)平均ICER升高13.3%。

临床怎么用

  • 作者认为未来疫苗成本效果分析应适当纳入家庭溢出效应,以反映疫苗的全部价值并支持循证决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We evaluated how frequently vaccine cost-effectiveness analyses (CEAs) include family spillover effects, costs or health impacts on family members who care for or about patients, and how their inclusion affects results. METHODS: Using the Tufts CEA Registry, we performed a systematic review to identify English-language CEAs published from January 2013 to December 2022 from the societal perspective. We selected CEAs for the four vaccines most evaluated within our search, examined how frequently these CEAs included family spillover effects, and how this inclusion changed CEA results. RESULTS: Among 268 vaccine CEAs meeting inclusion criteria, the top four vaccines were: human papillomavirus (n = 21), influenza (n = 57), pneumococcal (n = 37), and rotavirus (n = 25). (137 studies, 51 % of total). Of these, 65 (47.4 %) included family spillover effects, predominately time costs (n = 64, 98.5 %). Only four studies (6.2 %) included family spillover health effects. From 30 studies, we created 266 pairs of incremental cost-effectiveness ratios (ICERs), with each pair consisting of one ICER calculated with and then without family spillover effects. We then compared each pair to assess the impact of including family spillover effects on the ICERs. With 29 ICERs (10.9 %), including family spillover changed the result from a positive ICER, with a positive cost and benefit, to cost-saving, with a negative cost and a positive benefit. In 30 cases (11.3 %), ICERs remained cost-saving and in 207 cases (77.8 %) ICERs remained positive, with and without spillover effects. Among these, 206 pairs (99.5 %) showed a mean ICER reduction of 18.8 %, while one pair (0.5 %) increased by 13.3 %. CONCLUSIONS: Approximately half of vaccine CEAs in our sample excluded family spillover effects. When included, most added family spillover costs but rarely family health effects, and generally showed more favorable results. Future vaccine CEAs should appropriately include family spillover effects to reflect vaccines' full value and support evidence-based decision-making.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Qian Y, Phillips M, Eiden AL, et al. Family spillover effects in cost-effectiveness analyses of vaccines. Vaccine. 2025. PMID: 40974734. doi:10.1016/j.vaccine.2025.127755

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。